Results 21 to 30 of about 3,256 (217)

Progression of radiographic fibrosis in rheumatoid arthritis-associated interstitial lung disease

open access: yesFrontiers in Medicine, 2023
Background and objectivesPreclinical interstitial lung disease (pILD) may represent the early stages of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Dandan Chai   +7 more
doaj   +1 more source

Comorbidities in unclassifiable interstitial lung disease

open access: yesRespiratory Research, 2022
Background Comorbidities are common in interstitial lung diseases (ILD) and have an important association with survival, but the frequency and prognostic impact of comorbidities in unclassifiable interstitial lung disease (uILD) remains elusive. We aimed
Thomas Skovhus Prior   +6 more
doaj   +1 more source

Efficacy and Tolerability of Methotrexate and Methylprednisolone in a Comparative Assessment of the Primary and Long-Term Outcomes in Patients with Pulmonary Sarcoidosis

open access: yesDiagnostics, 2021
Background: There is insufficient information in the literature on the comparative efficacy and tolerability of methotrexate (MTX) and methylprednisolone (MP) in patients with pulmonary sarcoidosis in assessing primary outcomes and the relapse rate ...
Volodymyr Gavrysyuk   +6 more
doaj   +1 more source

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis

open access: yesEuropean Respiratory Review, 2019
Two antifibrotic medications (nintedanib and pirfenidone) were recommended (conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the 2015 IPF evidence-based guidelines.
Bridget F. Collins, Ganesh Raghu
doaj   +1 more source

The Role of Cutibacterium acnes in Sarcoidosis: From Antigen to Treatable Trait?

open access: yesMicroorganisms, 2022
Cutibacterium acnes (C. acnes, formerly Propionibacterium acnes) is considered to be a non-pathogenic resident of the human skin, as well as mucosal surfaces. However, it also has been demonstrated that C.
Raisa Kraaijvanger, Marcel Veltkamp
doaj   +1 more source

Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis

open access: yesMedical Sciences, 2018
Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause, is the most common and deadly of the idiopathic interstitial pneumonias.
Estrella Fernández Fabrellas   +3 more
doaj   +1 more source

Interstitial lung diseases in children

open access: yesLa Presse Médicale, 2020
Interstitial lung disease (ILD) in children (chILD) is a heterogeneous group of rare respiratory disorders that are mostly chronic and associated with high morbidity and mortality. The pathogenesis of the various chILD is complex and the diseases share common features of inflammatory and fibrotic changes of the lung parenchyma that impair gas exchanges.
Nadia, Nathan   +4 more
openaire   +3 more sources

Metastatic niche shaped by host factors influences disseminated cancer cell fate

open access: yesFEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward   +2 more
wiley   +1 more source

The therapy of idiopathic pulmonary fibrosis: what is next?

open access: yesEuropean Respiratory Review, 2019
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease, characterised by progressive scarring of the lung and associated with a high burden of disease and early death.
Vivien Somogyi   +5 more
doaj   +1 more source

Neutralization of the PTX3/CD44 axis suppresses TGF‐β1 signaling in kidney fibrosis

open access: yesFEBS Letters, EarlyView.
This study investigates how the PTX3/CD44 axis promotes kidney fibrosis by activating TGF‐β1 signaling. We demonstrate that the neutralizing antibody WHC‐001 effectively inhibits this pathway, suppressing myofibroblast activation and partial epithelial–mesenchymal transition (EMT).
Chao‐Chun Cheng   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy